<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8809320</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1600</journal-id>
<journal-id journal-id-type="nlm-ta">Neuron</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuron</journal-id>
<journal-title-group>
<journal-title>Neuron</journal-title>
</journal-title-group>
<issn pub-type="ppub">0896-6273</issn>
<issn pub-type="epub">1097-4199</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30359605</article-id>
<article-id pub-id-type="pmc">6989093</article-id>
<article-id pub-id-type="doi">10.1016/j.neuron.2018.10.015</article-id>
<article-id pub-id-type="manuscript">NIHMS1510173</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Lost in translation: Traversing the complex path from genomics to therapeutics in Autism Spectrum Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sestan</surname>
<given-names>Nenad</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>State</surname>
<given-names>Matthew W.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Neuroscience and Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, CT 06510</aff>
<aff id="A2"><label>2</label>Department of Psychiatry, Langley Porter Psychiatric Institute, Quantitative Biology Institute, and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA 94143</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence to: <email>Nenad.Sestan@yale.edu</email> and <email>Matthew.State@ucsf.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P78">Declaration of Interests</p>
<p id="P79">Matthew W. State serves on the scientific advisory boards and has stock or stock options for BlackThorn therapeutics and ARett pharmaceuticals.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>22</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>24</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>1</month>
<year>2020</year>
</pub-date>
<volume>100</volume>
<issue>2</issue>
<fpage>406</fpage>
<lpage>423</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuron.2018.10.015-->
<abstract id="ABS1">
<title>Summary</title>
<p id="P1">Recent progress in the genomics of non-syndromic autism spectrum disorder (nsASD) highlights rare large-effect heterozygous <italic>de novo</italic> coding mutations. This distinguishes nsASD from later-onset psychiatric disorders where gene discovery efforts have predominantly yielded common alleles of small effect. These differences point to distinctive opportunities for clarifying the neurobiology of nsASD and developing novel treatments. We argue that the path ahead also presents key challenges, including distinguishing human pathophysiology from the potentially pleiotropic neurobiology mediated by established risk genes. We present our view of some of the conceptual limitations of traditional studies of model organisms, suggest a strategy focused on investigating the convergence of multiple nsASD genes, and propose that the detailed characterization of the molecular and cellular landscapes of developing human brain is essential to illuminate underlying mechanisms. Finally, we address how recent advances are leading to novel strategies for therapeutics that target various points along the path from genes to behavior.</p>
</abstract>
<abstract abstract-type="summary" id="ABS2">
<title>In Brief:</title>
<p id="P2">Sestan and State propose that the distinctive genomic findings in Autism Spectrum Disorder, the deepening understanding of developing human brain, and the identification of spatiotemporal convergence of large-effect risk genes will help clarify pathophysiological mechanisms and identify novel treatment approaches.</p>
</abstract>
<kwd-group>
<kwd>Autism Spectrum Disorder</kwd>
<kwd><italic>de novo</italic> mutation</kwd>
<kwd>genomics</kwd>
<kwd>neurodevelopmental disorders</kwd>
<kwd>convergence</kwd>
<kwd>non-syndromic autism spectrum disorder</kwd>
<kwd>human brain development</kwd>
<kwd>transcriptomics</kwd>
<kwd>gene therapy</kwd>
<kwd>convergence neuroscience</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>